HP25LAPAROSCOPIC SLEEVE GASTRECTOMY FOR MORBIDLY OBESE PATIENTS

Obesity surgery is been endorsed as the only effective method of weight reduction in morbidly obese patients. Laparoscopic Roux-en-Y gastric bypass (LRYGBP) is been used as the most effective procedures in our centre. However LRYGBP also conveys high risk of peri- and postoperative complications on obese patients. Laparoscopic sleeve gastrectomy (LSG) is been employed first-stage procedure as a risk reduction strategy. The aim of this study was to report the short-term outcomes of LSG, its effect on risk reduction and resolution in co-morbidities. We prospectively investigated 92 patients who underwent LSG between July 2004 and February 2006 and completed our data collection through 3- to 6-monthly follow up and/or patient questionnaire. Data collected included demographics, degree of weight reduction, postoperative complications, and changes in co-morbidities. Median BMI was 52.03 kg/m2 (33-82). 56% patients had a BMI >50 kg/m2. The median postoperative excess weight loss (EWL) was 45% with 35.49% at 6 months, 49.07% at 12 months, and 55.75% at 18 months. 39% of patients had resolutions in Diabetes Mellitus type 2, 56% had resolutions in dyslipidaemia, 28% in hypertension, 66% in obstructive sleep apnoea. Complication rate of 7.5% and three patients necessitated surgical intervention. There was zero mortality. LSG minimizes postoperative complication rates significantly on high risk patients and achieves effective short-term weight loss with resolutions in co-morbidities. Additional studies are required to evaluate LSG as a stand-lone procedure. [PUBLICATION ABSTRACT]